Table 4.
Anti-cancer potentiality (pIC50) of best in-house synthesized pyrazole derivatives predicted based on derived 2D-QSAR model of each cancer cell line.
| Cancer Cell line/Cancer types | pIC50 value of the best potential inhibitors for each cell line | |||
|---|---|---|---|---|
| PC-3/Prostate cancer | M48 = 5.26 | M55 = 5.32 | M60 = 5.26 | M54 = 5.14 |
| B16F10/Skin cancer | M36 = 6.75 | M41 = 6.51 | M42 = 6.30 | M43 = 6.73 |
| K562/Leukemia | M1 = 7.31 | |||
| MDA-MB-231/Breast cancer | M4 = 6.36 | M5 = 5.89 | M32 = 7.03 | M33 = 6.55 |
| A2780/Ovarian cancer | M4 = 8.57 | M19 = 8.57 | M30 = 8.15 | M32 = 8.63 |
| ACHN/Kidney cancer | M1 = 6.10 | M5 = 6.48 | M20 = 5.87 | M33 = 6.36 |